Clinical trial

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

NCT00013663

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention ALVAC(2)120(B,MN)GNP (vCP1452) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Aldesleukin Normalized identity: aldesleukinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE2

Conditions

HIV Infectionsunresolved

Interventions

ALVAC(2)120(B,MN)GNP (vCP1452)BIOLOGICAL

AldesleukinDRUG · verified · RxNorm: aldesleukin

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

New York Presbyterian Hospitalcollaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00013663 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.